The abstract is read at the publisher; the summary is JClub's.
A CAR-restricted CRISPRa expansion platform enables genome-wide CRISPRa-CAR T survival screens with ~10 9 cells, sustaining >85% on-target overexpression across cytokine milieus.
- Why it matters: Extending CAR T success beyond B malignancies requires improving persistence, but genome-wide CRISPRa surveys in primary T cells have been constrained by cell demands and short-lived activity.
- What they did: The authors used divergent duplicate elongation factor 1α hybrid promoters and late lentiviral guide RNA delivery to run survival-based genome-wide screens across varied tumor cytokine levels.
- The result: The screens nominate endogenous genes linked to enhanced CAR T persistence under different cytokine conditions, and GSE1’s survival effect is preserved using a clinically relevant transgene overexpression strategy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 opens in JClub
- Open access